



# U.S. Physical Therapy, Inc. (USPH)

Updated November 19<sup>th</sup>, 2025, by Nathan Parsh

## Key Metrics

|                             |      |                                             |             |                                  |          |
|-----------------------------|------|---------------------------------------------|-------------|----------------------------------|----------|
| <b>Current Price:</b>       | \$68 | <b>5 Year Annual Expected Total Return:</b> | 10.3%       | <b>Market Cap:</b>               | \$1.0 B  |
| <b>Fair Value Price:</b>    | \$92 | <b>5 Year Growth Estimate:</b>              | 2.0%        | <b>Ex-Dividend Date:</b>         | 11/17/25 |
| <b>% Fair Value:</b>        | 74%  | <b>5 Year Valuation Multiple Estimate:</b>  | 6.2%        | <b>Dividend Payment Date:</b>    | 12/12/25 |
| <b>Dividend Yield:</b>      | 2.6% | <b>5 Year Price Target</b>                  | \$102       | <b>Years Of Dividend Growth:</b> | 5        |
| <b>Dividend Risk Score:</b> | F    | <b>Sector:</b>                              | Health Care | <b>Rating:</b>                   | Hold     |

## Overview & Current Events

Founded in 1990, U.S. Physical Therapy is a leading provider of outpatient rehabilitation services. As of the end of the second quarter, the company owned or managed 768 outpatient physical therapy clinics in 44 states. U.S. Physical Therapy provides preventative and post-operative care for a wide variety of orthopedic-related disorders, sports-related injuries, neurologically-related injuries, and rehabilitation for those injured at work as well as industry injury prevention services. The physical therapy business accounts for more than 80% of annual revenue with injury prevention contributing the remainder.

On November 5<sup>th</sup>, 2025 U.S. Physical Therapy reported third quarter results. For the quarter, revenue grew 17.3% to \$197.1 million, which was \$3.2 million better than expected. Adjusted earnings-per-share of \$0.66 compared unfavorably to \$0.69 in the prior year and was in-line with estimates.

Shares have sold off sharply since the earnings release, likely due to the year-over-year decline in profitability. For the quarter, physical therapy revenue grew 17.8% while injury prevention was up 14.6%. Visits per clinic per day increased to a record 32.2 from 30.1 in the prior year. U.S. Physical Therapy’s clinics had nearly 4.6 million visits for the first nine months of 2025. The company recorded more than 1.5 million clinic visits and more than 30,000 home care visits during Q3. Part of this growth was due to the acquisition of a net 61 clinics compared to the first three quarters of last year. The net rate per patient visit of \$105.54 was just behind the \$105.65 figure the company recorded in Q3 2024. Salaries and related costs were down 0.6%.

U.S. Physical Therapy is projected to earn \$2.63 per share in 2025, down from \$2.75 previous. This would mark an improvement of 32.2% from 2024. We have updated our forecast accordingly.

## Growth on a Per-Share Basis

| Year                      | 2015   | 2016   | 2017   | 2018   | 2019   | 2020   | 2021   | 2022   | 2023   | 2024   | 2025          | 2030          |
|---------------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|---------------|---------------|
| <b>EPS</b>                | \$1.68 | \$1.72 | \$1.79 | \$1.21 | \$2.45 | \$2.70 | \$2.56 | \$2.61 | \$2.11 | \$1.99 | <b>\$2.63</b> | <b>\$2.90</b> |
| <b>DPS</b>                | \$0.60 | \$0.68 | \$0.80 | \$0.92 | \$1.14 | \$0.32 | \$1.46 | \$1.64 | \$1.72 | \$1.76 | <b>\$1.80</b> | <b>\$1.99</b> |
| <b>Shares<sup>1</sup></b> | 12     | 13     | 13     | 13     | 13     | 13     | 13     | 13     | 14     | 15     | <b>15</b>     | <b>15</b>     |

Consistent earnings growth for U.S. Physical Therapy has been difficult to maintain. The company saw largely steady growth from 2015 onward before hitting a new high in 2020. Since then, earnings-per-share have been in a downward trajectory. As such, U.S. Physical Therapy’s earnings-per-share have a compound annual growth rate of 1.9% since 2015, but lower by 0.5% over the last five years.

That said, the company is expected to set a new high for earnings-per-share this year. The physical therapy space is highly fragmented with few large players. This gives U.S. Physical Therapy an opportunity to consolidate and buy additional businesses. For example, the company purchased a 40% interest in an industrial injury prevention business in April of this year. Last October, U.S. Physical Therapy took a 50% interest in MSO Metro, which manages 50 physical therapy clinics in New York. The company believes the rehabilitation market is greater than \$40 billion, which could allow for an immense amount of future growth.

<sup>1</sup> In millions.

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



# U.S. Physical Therapy, Inc. (USPH)

Updated November 19<sup>th</sup>, 2025, by Nathan Parsh

U.S. Physical Therapy also is diversified geographically. The company operates in more than 44 states with its largest cluster of facilities located in Tennessee, Texas, Michigan, New York, Virginia, and Oregon. The company does not operate a physical therapy facility in California, but does partner with private practices in the state. U.S. Physical Therapy does have an industrial injury prevention services segment in the state.

Offsetting these tailwinds working in its favor with the lackluster EPS growth over the last decade, we believe that 2% earnings growth is achievable. Dividend growth, which has slowed to \$0.01 per share per quarter over the past few years, is likely to grow by at least a similar rate to earnings over the next five years. The company did suspend its dividend in 2020 during the pandemic before reinstating it the very next year.

## Valuation Analysis

| Year      | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Now  | 2030 |
|-----------|------|------|------|------|------|------|------|------|------|------|------|------|
| Avg. P/E  | 32.1 | 41.3 | 41.3 | 77.7 | 46.7 | 48.5 | 39.6 | 35.9 | 69.5 | 48.2 | 25.9 | 35.0 |
| Avg. Yld. | 1.1% | 1.0% | 1.1% | 0.9% | 1.0% | 1.0% | 1.5% | 2.0% | 1.9% | 2.0% | 2.6% | 2.0% |

Shares of U.S. Physical Therapy are down \$24, or 26%, since our October 15<sup>th</sup>, 2025 report. The stock has often had an elevated price-to-earnings multiple even as EPS growth has been minimal over the long-term. The average price-to-earnings ratio over both the last 10- and five-year periods of time is ~48. We believe a more reasonable fair value is closer to 35 times earnings. Reaching our target multiple by 2030 would add 6.2% to annual returns over this period. Shares yield 2.6% currently, which is one of the highest yields that the stock has offered in the last decade.

## Safety, Quality, Competitive Advantage, & Recession Resiliency

| Year   | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2030 |
|--------|------|------|------|------|------|------|------|------|------|------|------|------|
| Payout | 36%  | 40%  | 45%  | 76%  | 47%  | 12%  | 57%  | 63%  | 82%  | 88%  | 68%  | 68%  |


U.S. Physical Therapy does enjoy some tailwinds, namely that it operates in a fragmented industry with a large total addressable market for services. People are likely to need more rehabilitation services as they age, which should provide U.S. Physical Therapy with a sizeable runway for growth.

U.S. Physical Therapy's payout ratio has jumped around a lot as earnings have fluctuated over the last decade and the company only made one payment during the worst of the COVID-19 pandemic. With earnings growth expected to return this year, we believe that the dividend is likely as safe as it has been in a few years. Total debt stands at just ~\$160 million, which appears to be reasonable.

## Final Thoughts & Recommendation

Following third quarter results, we project that U.S. Physical Therapy will return 10.3% annually over the next five years, up from 4.7% previously. The company posted growth in most areas of its business during the most recent quarter, but we continue to rate U.S. Physical Therapy as a hold rating due to a very low dividend risk score.

## Total Return Breakdown by Year



Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



# U.S. Physical Therapy, Inc. (USPH)

Updated November 19<sup>th</sup>, 2025, by Nathan Parsh

## Income Statement Metrics

| Year             | 2015  | 2016  | 2017  | 2018  | 2019  | 2020  | 2021  | 2022  | 2023  | 2024  |
|------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Revenue          | 331   | 357   | 414   | 454   | 482   | 423   | 495   | 553   | 605   | 671   |
| Gross Profit     | 83    | 86    | 95    | 106   | 107   | 92    | 111   | 103   | 112   | 130   |
| Gross Margin     | 25.0% | 24.2% | 22.9% | 23.4% | 22.3% | 21.9% | 22.4% | 18.6% | 18.5% | 19.4% |
| SG&A Exp.        | 31    | 32    | 36    | 41    | 45    | 42    | 47    | 46    | 52    | 58    |
| D&A Exp.         | 8     | 9     | 10    | 10    | 10    | 11    | 12    | 15    | 16    | 19    |
| Operating Profit | 48    | 50    | 55    | 60    | 67    | 56    | 71    | 66    | 70    | 66    |
| Op. Margin       | 14.3% | 13.9% | 13.4% | 13.3% | 14.0% | 13.3% | 14.3% | 11.9% | 11.5% | 9.8%  |
| Net Profit       | 26    | 26    | 28    | 55    | 60    | 54    | 61    | 44    | 41    | 47    |
| Net Margin       | 8.0%  | 7.4%  | 6.7%  | 12.2% | 12.5% | 12.7% | 12.4% | 8.0%  | 6.7%  | 7.0%  |
| Free Cash Flow   | 31    | 43    | 49    | 66    | 52    | 92    | 68    | 52    | 74    | 67    |
| Income Tax       | 14    | 12    | 6     | 11    | 14    | 13    | 15    | 12    | 12    | 15    |

## Balance Sheet Metrics

| Year               | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023  | 2024  |
|--------------------|------|------|------|------|------|------|------|------|-------|-------|
| Total Assets       | 306  | 354  | 421  | 446  | 586  | 621  | 780  | 889  | 1,028 | 1,207 |
| Cash & Equivalents | 16   | 20   | 22   | 23   |      | 33   | 29   | 32   | 153   | 41    |
| Acc. Receivable    | 36   | 39   | 45   | 45   | 46   | 42   | 46   | 52   | 52    | 59    |
| Inventories        | -    | -    | -    | -    |      | -    | -    | -    | -     | -     |
| Goodwill & Int.    | 202  | 265  | 320  | 342  | -    | 402  | 521  | 603  | 619   | 846   |
| Total Liabilities  | 88   | 96   | 112  | 95   |      | 211  | 327  | 404  | 376   | 448   |
| Accounts Payable   | 2    | 2    | 2    | 2    | 2    | 1    | 6    | 7    | 4     | 6     |
| Long-Term Debt     | 49   | 52   | 61   | 40   | 138  | 111  | 223  | 295  | 259   | 295   |
| Total Equity       | 171  | 188  | 205  | 216  | 240  | 276  | 296  | 316  | 476   | 489   |
| LTD/E Ratio        | 0.29 | 0.28 | 0.30 | 0.18 | 0.57 | 0.40 | 0.75 | 0.94 | 0.54  | 0.60  |

## Profitability & Per Share Metrics

| Year             | 2015  | 2016  | 2017  | 2018  | 2019  | 2020  | 2021  | 2022  | 2023  | 2024  |
|------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Return on Assets | 9.6%  | 8.0%  | 7.2%  | 12.8% | 11.7% | 8.9%  | 8.7%  | 5.3%  | 4.2%  | 4.2%  |
| Return on Equity | 13.5% | 11.0% | 9.8%  | 16.8% | 16.5% | 13.6% | 14.2% | 9.5%  | 7.2%  | 6.6%  |
| ROIC             | 11.3% | 9.2%  | 8.2%  | 14.6% | 15.7% | 11.9% | 10.2% | 6.1%  | 4.8%  | 4.8%  |
| Shares Out.      | 12    | 13    | 13    | 13    | 13    | 13    | 13    | 13    | 14    | 15    |
| Revenue/Share    | 26.74 | 28.52 | 32.94 | 35.84 | 37.78 | 32.95 | 38.38 | 42.60 | 42.63 | 44.57 |
| FCF/Share        | 2.52  | 3.42  | 3.93  | 5.20  | 4.10  | 7.20  | 5.30  | 3.97  | 5.18  | 4.44  |

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

### Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.